The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy for autoimmune cytopenias. RXIM002 represents the world's first circular RNA-based in vivo CAR-T therapy achieving FDA IND clearance. RiboX expands its clinical-stage pipeline through its proprietary...
TAIPEI, June 25, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, announces the availability of the MO32U24. This 32-inch 240Hz 4K gaming monitor...
KITCHENER, ON, June 25, 2026 /PRNewswire/ -- Canadian Solar Inc. (the "Company" or "Canadian Solar") (NASDAQ: CSIQ) today announced that e-STORAGE, its energy storage solutions business,...
BEIJING, June 25, 2026 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN), a leading used car retailer in China, today hosted its...
XIAMEN, China, June 25, 2026 /PRNewswire/ -- High Templar Tech Limited (the "Company," "High Templar" or "we") (NYSE: HTT), announced today the preliminary results...